#CROI 2017

Other factors linked to a reduced risk of death include a hep C cure, less advanced liver disease, not smoking and well treated HIV.

In a small study with HCV/HIV-negative participants, G/P did not significantly interact with the drugs in Genvoya or Triumeq.

On the flip side, a recent study found that hep C treatment was associated with rising cholesterol.

But not as well as those with compensated cirrhosis or no cirrhosis.

However, in a recent study those who had been treated for hep C before did not fare as well.

Eighty-five percent of IDUs receiving hep C therapy at a New York City syringe exchange program were cured.

A look at the most notable HIV-related studies presented at the 2017 Conference on Retroviruses and Opportunistic Infections in Seattle.

The DC area’s MedStar Health attempted to significantly improve the rate of hepatitis C testing among baby boomers, who are at higher risk.

Highlights from the hep C–related studies presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle

Hep C infection routes among this population apparently overlap with those of their HIV-positive peers.

However, in a recent small study, hepatitis C treatment was not associated with an improvement in cognitive impairment in this population.

Researchers analyzed factors associated with testing positive for HIV following a hepatitis C diagnosis.

Highly effective hepatitis C cures have apparently succeeded in breaking up transmission networks among this population.

This feat could take only a decade, although hepatitis C treatment must be ramped up among gay and bi men at high risk of reinfection.

Watch for data being released at the annual Conference on Retroviruses and Opportunistic Infections (CROI) February 13 to 16.